The trial enrolled and treated 101 immunocompromised patients with refractory or resistant HSV infection.

Pritelivir met its primary endpoint of superior lesion healing, achieving a 62.7% lesion healing rate compared to 34.0% with standard-of-care ...

Investigational antiviral pritelivir demonstrates efficacy and improved tolerability over current treatments for refractory HSV in high-risk patients.

Learn what scientific research and experts say about the evidence for common home remedies for herpes, including honey, lemon balm, and petroleum jelly.

In the mid-1990s, researchers identified the viral helicase–primase enzyme complex as a target for a potential anti-herpes simplex virus (HSV) therapy. Three decades later, the first promising ...

Pritelivir demonstrated clinically meaningful and highly statistically significant superiority (p=0.0047) in lesion healing up to 28 days of treatment, compared with standard-of-care (SoC) treatments ...

Full abstracts will be released on February 4, 2026, at 7:00 am CET/1:00 am EST and will be available via the conference website here .

Herpes simplex virus-1 (HSV-1) reactivation is common among patients with hematologic malignancies. 1,2 Risk factors include mucosal disruption (e.g., after chemotherapy) and neutropenia. 1 The report ...

Genital herpes infections are very common. There are 42 million new infections each year — that averages out to one new person infected each second. While treatments can help with symptoms, there's no ...

– ABI-5366 is currently being evaluated in ongoing Phase 1b clinical trial with interim proof-of-concept data expected in fall 2025 – SOUTH SAN FRANCISCO, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- ...

Theralase® validates previous University of Manitoba research by demonstrating that RuvidarTM is safe and effective in the treatment of the Herpes Simplex Virus in an animal model. TORONTO, ON / ...